Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (801-810 of 962) with videos related to

Pageof 97
Sort By:
American Heart Journal|November 26, 2013
Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary interventionPhilippe Gabriel Steg, Arnoud van 't Hof, Peter Clemmensen, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Circulation|August 29, 2017
Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015Etienne Puymirat, Tabassome Simon, Guillaume Cayla, et al.
Circulation|March 18, 2020
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)Kevin R Bainey, Robert C Welsh, Stuart J Connolly, et al.
JACC. Cardiovascular Interventions|March 7, 2020
DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCIPly Chichareon, Rodrigo Modolo, Hideyuki Kawashima, et al.
Circulation|September 3, 2019
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary SyndromesMatthew T Roe, Qian H Li, Deepak L Bhatt, et al.
European Heart Journal|December 8, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trialsFrancesco Costa, Claudio Montalto, Mattia Branca, et al.
Annals of Internal Medicine|June 21, 2021
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized TrialMichael Szarek, Deepak L Bhatt, Ph Gabriel Steg, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|May 25, 2022
Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analysesIsabelle Durand-Zaleski, Gregory Ducrocq, Maroua Mimouni, et al.
Circulation. Cardiovascular Interventions|June 6, 2018
Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)Usman Baber, Shawn X Li, Rebecca Pinnelas, et al.
Pageof 97

Showing results (801-810 of 962) with videos related to

Sort By:
Pageof 97
American Heart Journal|November 26, 2013
Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary interventionPhilippe Gabriel Steg, Arnoud van 't Hof, Peter Clemmensen, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Circulation|August 29, 2017
Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015Etienne Puymirat, Tabassome Simon, Guillaume Cayla, et al.
Circulation|March 18, 2020
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)Kevin R Bainey, Robert C Welsh, Stuart J Connolly, et al.
JACC. Cardiovascular Interventions|March 7, 2020
DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCIPly Chichareon, Rodrigo Modolo, Hideyuki Kawashima, et al.
Circulation|September 3, 2019
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary SyndromesMatthew T Roe, Qian H Li, Deepak L Bhatt, et al.
European Heart Journal|December 8, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trialsFrancesco Costa, Claudio Montalto, Mattia Branca, et al.
Annals of Internal Medicine|June 21, 2021
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized TrialMichael Szarek, Deepak L Bhatt, Ph Gabriel Steg, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|May 25, 2022
Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analysesIsabelle Durand-Zaleski, Gregory Ducrocq, Maroua Mimouni, et al.
Circulation. Cardiovascular Interventions|June 6, 2018
Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)Usman Baber, Shawn X Li, Rebecca Pinnelas, et al.
Pageof 97